Abstract
Background
Recent investigations have linked elevated gastrin levels to the improvement of type 2 diabetes mellitus (T2DM). Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy (SG) are effective treatments for T2DM, but it is not known if this is related to postoperative alterations of gastrin secretion.
Methods
Twenty women previously operated with RYGB or SG and 13 female controls were enrolled and evaluated for body mass index, lipids, C-peptide, HbA1c, and anti-H. pylori IgG. Glucose, gastrin, insulin, and glucagon-like peptide 1 (GLP-1) concentrations were measured before and 30, 60, 90, and 120 min after ingestion of a protein-rich mixed meal.
Results
Six participants primarily selected were excluded due to usage of proton pump inhibitors, positive H.pylori IgG, or history of T2DM, yielding the following groups: RYGB (n = 9), SG (n = 8), and controls (n = 10). There were no differences in age, body mass index, HbA1c, or C-peptide levels between groups. RYGB had significantly lower area under the curve (AUC) for glucose during the test compared to controls (p = 0.013). RYGB showed lower serum gastrin levels compared to SG and controls (p < 0.05 for all). There was a non-significant increased gastrin release in SG compared to controls (p = 0.091). For SG and controls, there was a negative correlation between glucose and gastrin response (p = 0.0043).
Conclusion
Gastrin secretion is diminished after RYGB. Hypergastrinemia was not present after SG, but a tendency of enhanced gastrin secretion was observed. These findings require further investigation in prospective studies.
Similar content being viewed by others
References
Guariguata L, Whiting DR, Hambleton I, et al. Global estimates of diabetes prevalence for 2013 and projections for 2035. Diab Res ClinPract Elsev Ireland Ltd. 2014;103:137–49.
Wild S, Gojka R, Green A, et al. Estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27:1047–53.
Sjöström L, Lindroos A-K, Peltonen M, et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med. 2004;351:2683–93.
Buchwald H, Estok R, Fahrbach K, et al. Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am J Med Elsev Inc. 2009;122:248–56.e5.
Schauer PR, Bhatt DL, Kirwan JP, et al. Bariatric surgery versus intensive medical therapy for diabetes—3-year outcomes. N Engl J Med. 2014;370:2002–13.
Ikramuddin S, Korner J, Lee W-J, et al. Roux-en-Y gastric bypass vs intensive medical management for the control of type 2 diabetes, hypertension, and hyperlipidaemia. JAMA. 2013;309:2240–9.
Knop FK, Taylor R. Mechanism of metabolic advantages after bariatric surgery: it’s all gastrointestinal factors versus it’s all food restriction. Diabetes Care. 2013;36:S287–91.
Romero F, Nicolau J, Flores L, et al. Comparable early changes in gastrointestinal hormones after sleeve gastrectomy and Roux-en-Y gastric bypass surgery for morbidly obese type 2 diabetic subjects. Surg Endosc. 2012;26:2231–9.
Feldman EJ, Grossman MI. Liver extract and its free amino acids equally stimulate gastric acid secretion. Am J Physiol. 1980;239:G493–6.
Richardson CT, Walsh JH, Hicks MI, et al. Studies on the mechanisms of food-stimulated gastric acid secretion in normal human subjects. J Clin Invest. 1976;58:623–31.
Håkanson R, Sundler F. Trophic effects of gastrin. Scand J Gastroenterol. 1991;26:130–6.
Waldum HL, Sandvik AK, Brenna E, et al. Gastrin-histamine sequence in the regulation of gastric acid secretion. Gut. 1991;32:698–701.
Rehfeld JF, Stadil F. The effect of gastrin on basal- and glucose-stimulated insulin secretion in man. J Clin Invest. 1973;52:1415–26.
Rehfeld JF. Incretin physiology beyond glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide: cholecystokinin and gastrin peptides. Acta Physiol (Oxf). 2011;201:405–11.
Rickels MR, Elahi D. Raising serum gastrin to improve glycemic control in (type 2) diabetes: another limb of the enteroinsular axis? J Clin Endocrinol Metab. 2012;97:3915–6.
Waldum HL, Fossmark R, Bakke I, et al. Hypergastrinemia in animals and man: causes and consequences. Scand J Gastroenterol. 2004;39:505–9.
Grong E, Arbo IB, Thu OKF, et al. The effect of duodenojejunostomy and sleeve gastrectomy on type 2 diabetes mellitus and gastrin secretion in Goto-Kakizaki rats. Surg Endosc. 2015;29:723–33.
Bevilacqua M, Dominguez LJ, Righini V, et al. Acute parathyroid hormone increase by oral peptones administration after Roux-en-Y gastric bypass surgery in obese subjects: role of phosphate in the rapid control of parathyroid hormone release. Surg Mosb Inc. 2010;147:655–61.
Sillakivi T, Suumann J, Kirsimägi Ü, et al. Plasma levels of gastric biomarkers in patients after bariatric surgery: biomarkers after bariatric surgery. Hepatogastroenterology. 2011;60:225–30.
Kleveland PM, Haugen SE, Waldum HL. The preparation of bioactive 125I-gastrin, using iodo-gen as oxidizing agent, and the use of this tracer in receptor studies. Scand J Gastroenterol. 1985;20:569–76.
Lamberts R, Brunner G, Solcia E. Effects of very long (up to 10 years) proton pump blockade on human gastric mucosa. Digestion. 2001;64:205–13.
Katelaris PH, Seow F, Lin BP, et al. Effect of age, Helicobacter pylori infection, and gastritis with atrophy on serum gastrin and gastric acid secretion in healthy men. Gut. 1993;34:1032–7.
Basso N, Capoccia D, Rizzello M, et al. First-phase insulin secretion, insulin sensitivity, ghrelin, GLP-1, and PYY changes 72 h after sleeve gastrectomy in obese diabetic patients: The gastric hypothesis. Surg Endosc. 2011;25:3540–50.
Choi E, Roland JT, Barlow BJ, et al. Cell lineage distribution atlas of the human stomach reveals heterogeneous gland populations in the gastric antrum. Gut. 2014;63:1711–20.
Holle GE, Stiegelmeier M, Reidel J, et al. Histologic, immunohistochemical and morphometric study of the mucosa of the total gastric antrum in patients with carcinoma of the stomach. Surg Gynecol Obs. 1993;176:65–72.
Borch K, Ahrén B, Ahlman H, et al. Gastric carcinoids. Ann Surg. 2005;242:64–73.
Erim T, Colak Y, Szomstein S. Gastric carcinoid tumor after laparoscopic sleeve gastrectomy. Surg Obes Relat Dis. 2015. doi:10.1016/j.soard.2015.06.016.
Arapis K, Cavin JB, Gillard L, et al. Remodeling of the residual gastric mucosa after Roux-en-Y gastric bypass or vertical sleeve gastrectomy in diet-induced obese rats. PLoS One. 2015;10:e0121414.
Bödvarsdóttir TB, Hove KD, Gotfredsen CF, et al. Treatment with a proton pump inhibitor improves glycaemic control in Psammomys obesus, a model of type 2 diabetes. Diabetologia. 2010;53:2220–3.
Mefford IN, Wade EU. Proton pump inhibitors as a treatment method for type II diabetes. Med Hypothes Elsev Ltd. 2009;73:29–32.
Boj-Carceller D, Bocos-Terraz P, Moreno-Vernis M, et al. Are proton pump inhibitors a new antidiabetic drug? A cross sectional study. World J Diab. 2011;2:217–20.
Barchetta I, Guglielmi C, Bertoccini L, et al. Therapy with proton pump inhibitors in patients with type 2 diabetes is independently associated with improved glycometabolic control. Acta Diabetol. 2015;52(5):873–80.
Han N, Oh M, Park SM, et al. The effect of proton pump inhibitors on glycated hemoglobin levels in patients with type 2 diabetes mellitus. Can J Diab Elsevier Ltd. 2015;39:24–8.
González-Ortiz M, Martínez-Abundis E, Mercado-Sesma AR, et al. Effect of pantoprazole on insulin secretion in drug-naïve patients with type 2 diabetes. Diabetes Res Clin Pract. 2015;108:e11–3.
Singh PK, Hota D, Dutta P, et al. Pantoprazole improves glycemic control in type 2 diabetes: a randomized, double-blind, placebo-controlled trial. J Clin Endocrinol Metab. 2012;97:E2105–8.
Hove KD, Brøns C, Færch K, et al. Effects of 12 weeks’ treatment with a proton pump inhibitor on insulin secretion, glucose metabolism and markers of cardiovascular risk in patients with type 2 diabetes: a randomised double-blind prospective placebo-controlled study. Diabetologia. 2013;56:22–30.
Carswell KA, Vincent RP, Belgaumkar AP, et al. The effect of bariatric surgery on intestinal absorption and transit time. Obes Surg. 2014;24:796–805.
Dirksen C, Damgaard M, Bojsen-Møller KN, et al. Fast pouch emptying, delayed small intestinal transit, and exaggerated gut hormone responses after Roux-en-Y gastric bypass. Neurogastroenterol Motil. 2013;25:346–e255.
Himpens J, Verbrugghe A, Cadière G-B, et al. Long-term results of laparoscopic Roux-en-Y gastric bypass: evaluation after 9 years. Obes Surg. 2012;22:1586–93.
Bojsen-Møller KN, Dirksen C, Jørgensen NB, et al. Early enhancements of hepatic and later of peripheral insulin sensitivity combined with increased postprandial insulin secretion contribute to improved glycemic control after Roux-en-Y gastric bypass. Diabetes. 2014;63:1725–37.
Stenström B, Zhao CM, Tømmerås K, et al. Is gastrin partially responsible for body weight reduction after gastric bypass? Eur Surg Res. 2006;38:94–101.
Peterli R, Steinert RE, Woelnerhanssen B, et al. Metabolic and hormonal changes after laparoscopic Roux-en-Y gastric bypass and sleeve gastrectomy: a randomized, prospective trial. Obes Surg. 2012;22:740–8.
Nannipieri M, Baldi S, Mari A, et al. Roux-en-Y gastric bypass and sleeve gastrectomy: mechanisms of diabetes remission and role of gut hormones. J Clin Endocrinol Metab. 2013;98:4391–9.
Jiménez A, Mari A, Casamitjana R, et al. GLP-1 and glucose tolerance after sleeve gastrectomy in morbidly obese subjects with type 2 diabetes. Diabetes. 2014;63:3372–7.
Fuchs HF, Broderick RC, Harnsberger CR, et al. Benefits of bariatric surgery do not reach obese men. J Am Coll Surg Am Coll Surg. 2014;219:e2.
Acknowledgments
This study would not have been feasible if not for the gastrin RIA analyses performed by biomedical laboratory scientist (BLS) Brit Schulze and BLS Anne Eleanor Kristensen. We would like to thank the staff at the Clinical Research Facility and Department of Medical Biochemistry, St. Olavs Hospital, Trondheim University Hospital for their professional and designated contribution in this study. Finally, we would like to thank the staff at the Department of Surgery and the Department of Medical Biochemistry at Namsos Hospital, Nord-Trøndelag Health trust, for the welcoming attitude and hardworking spirit throughout this experiment. This study has been funded internally by the Centre for Obesity and Innovation (ObeCe) and the Norwegian National Advisory Unit on Advanced Laparoscopic Surgery (NSALK), St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway; the Department of Cancer Research and Molecular Medicine (IKM), Norwegian University of Science and Technology (NTNU), Trondheim, Norway, and the Department of Surgery Namsos Hospital, Nord Trøndelag Health Trust, Namsos, Norway.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
The study was approved by the Regional Ethics Committee for medical research (REK 2013/2168). Informed consent was obtained from all individual participants included in the study on the test day. All procedures performed in the studies involving human participants were in accordance with the ethical standards of the regional national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Conflicts of Interest
MS Eivind Grong, MD Hallvard Græslie, BLS Bjørn Munkvoll, BLS Ingerid Brænne Arbo, MD Bård Kulseng, MD Helge L. Waldum and MD Ronald Mårvik have no conflicts of interest or financial ties to disclose.
Rights and permissions
About this article
Cite this article
Grong, E., Græslie, H., Munkvold, B. et al. Gastrin Secretion After Bariatric Surgery—Response to a Protein-Rich Mixed Meal Following Roux-En-Y Gastric Bypass and Sleeve Gastrectomy: a Pilot Study in Normoglycemic Women. OBES SURG 26, 1448–1456 (2016). https://doi.org/10.1007/s11695-015-1985-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11695-015-1985-z